Brazil has an increasing role as a political and economic actor in developed and developing countries, sustaining its long-standing commitment in ensuring access to medicines and vaccines at the domestic, regional, and international level. The Ministry of Health’s strategy includes the promotion of Brazil’s science and technology complex, the country’s presence in multilateral health forums and engagement in international health issues, regional health integration and international humanitarian health support. Brazil’s state-owned vaccine manufacturer Bio-Manguinhos is a supplier of the yellow fever vaccine to Gavi.
As part of its international engagement strategy to strengthen global immunization efforts, in 2006 Brazil pledged USD 20 million over 20 years to IFFIm. Legislative approval was granted by Congress on 31 May 2011 to allow Brazil to make contributions to Gavi, completing the first payment in November 2018.
Note: Proceeds are funds made available to Gavi from donor contributions and commitments, either through cash payments made to Gavi, through frontloading via the capital markets of a future donor commitment to IFFIm, or through AMC funds released to Gavi via the World Bank. IFFIm proceeds are allocated over five-year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile.
Click on Direct, IFFIm, AMC or Matching Fund in the above key to toggle their data on the graph, click again to show the data
Direct Contributions (including Matching Fund)
Received contributions: non-US$ contributions for 2000-2020 and Q1 2021 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014-2020 and Q1 2021 where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement.
Future contributions (for pledges made prior to the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q2-Q4 2021 and years 2021 and beyond are expressed in US$ equivalents using the applicable forecast rates from Bloomberg as at 31 March 2021 or using the rates applicable to any hedge agreement in place.
Future contributions (for pledges at the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q2-Q4 2021 and for years 2021 and beyond are expressed in US$ equivalents using the spot rates from Bloomberg as at 31 March 2021 or using the rates applicable to any hedge agreement in place.
Received contributions: non-US$ contributions for 2000-2020 and for Q1 2021 are expressed in US$ equivalents as confirmed by the IBRD (World Bank)
'Future contributions: non-US$ contributions for Q2-Q4 2021 and for years 2021 and beyond are expressed in US$ equivalents as follows:
For signed contribution agreements: contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements.
For contribution agreements not yet signed: contributions are expressed in US$ equivalents using the applicable spot rates from Bloomberg as at 31 March 2021.
Due to IFFIm’s nature as a frontloading vehicle, yearly contributions paid into IFFIm can differ significantly from yearly proceeds transferred to Gavi.
While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the amount due by the donor in the event that a Gavi-supported programme country is in protracted arrears with the International Monetary Fund. IFFIm donor grant payments made during Q1 2021 were accordingly reduced by 0.5%, reflecting the number of these countries in arrears during that time. However, as the number of these countries in protracted arrears with the IMF can evolve, Gavi is not taking any assumption on future grant reduction value and reports future grants payable in full as indicated in the respective grant agreements.